We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland. At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.


This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Sheikh, A., Robertson, C. & Taylor, B. 2021, 'BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant', New England Journal of Medicine. https://doi.org/10.1056/NEJMc2113864

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 16 June 2022
Was this page helpful?